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Abstract
CaMKII was suggested to mediate ischemic myocardial injury and
adverse cardiac remodeling. Here, we investigated the roles of
different CaMKII isoforms and splice variants in ischemia/reperfu-
sion (I/R) injury by the use of new genetic CaMKII mouse models.
Although CaMKIIdC was upregulated 1 day after I/R injury, cardiac
damage 1 day after I/R was neither affected in CaMKIId-deficient
mice, CaMKIId-deficient mice in which the splice variants CaMKIIdB
and C were re-expressed, nor in cardiomyocyte-specific CaMKIId/c
double knockout mice (DKO). In contrast, 5 weeks after I/R, DKO
mice were protected against extensive scar formation and cardiac
dysfunction, which was associated with reduced leukocyte infiltra-
tion and attenuated expression of members of the chemokine (C-C
motif) ligand family, in particular CCL3 (macrophage inflammatory
protein-1a, MIP-1a). Intriguingly, CaMKII was sufficient and
required to induce CCL3 expression in isolated cardiomyocytes,
indicating a cardiomyocyte autonomous effect. We propose that
CaMKII-dependent chemoattractant signaling explains the effects
on post-I/R remodeling. Taken together, we demonstrate that
CaMKII is not critically involved in acute I/R-induced damage but in
the process of post-infarct remodeling and inflammatory processes.
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Introduction
CaM Kinase II (CaMKII) is a serine/threonine protein kinase with
a broad spectrum of substrates (Braun & Schulman, 1995; Means,
2000). It is activated by Ca2+/calmodulin, direct oxidation and a
b-arrestin-dependent mechanism (De Koninck & Schulman, 1998;
Erickson et al, 2008; Mangmool et al, 2010; He et al, 2011). The
four isoforms of CaMKII (a, b, c, and d) are encoded by different
genes, which display distinct but overlapping expression patterns
(Tombes et al, 2003). CaMKIId and c are the predominant CaMKII
isoforms in the heart with CaMKIId displaying the highest level of
expression. Alternative splicing mechanisms provide subcellular
targeting to locations such as the nucleus (CaMKIIdB) or cytosolic
compartments (CaMKIIdC) (Tombes et al, 2003). Cardiomyocyte
apoptosis was suggested to be mediated through the cytosolic
CaMKIIdC splice variant via a mitochondrial cell death pathway
(Zhu et al, 2003, 2007). Transgenic cardiac overexpression
of CaMKIIdC leads to dilated cardiomyopathy (Zhang et al,
2003) and arrhythmias (Sossalla et al, 2011). The nuclear coun-
terpart CaMKIIdB was shown to be downregulated after myo-
cardial ischemia/reperfusion (I/R) in rats (Peng et al, 2010).
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Interestingly, CaMKIIdB has been even implicated to suppress
apoptosis by inducing the anti-apoptotic proteins Bcl-2 and HSP70
(Little et al, 2009) and to induce pathological cardiac remodeling
by phosphorylation of histone deacetylase 4 (HDAC4) (Backs
et al, 2006; Zhang et al, 2007). In macrophages, CaMKIIc links ER
stress with Fas and mitochondrial apoptosis pathways (Timmins
et al, 2009), but the specific role of CaMKIIc in cardiomyocytes
has not been investigated. Recently, it was shown that mitochon-
drial CaMKII can bind and regulate the mitochondrial Ca2+
uniporter (MCU), upregulating its activity by phosphorylation of
the channel N terminus. Furthermore, transgenic expression of a
mitochondrial-targeted CaMKII inhibitory peptide protected against
cardiac I/R injury (Joiner et al, 2012). In the context of subcellu-
lar localization of CaMKII and CaMKIId splice variants, it was
shown that—despite differences in the quantities of CaMKIId
splice variants in the nucleus, SR, cytosol, or mitochondria—both
dB and dC can be found at some proportion in each compartment
(Mishra et al, 2011). However, it remains unclear which CaMKII
isoform plays the leading role in mitochondria and whether
CaMKII levels (or proportions of its splice variants) are regulated
during pathological stress such as I/R injury (Correll & Molkentin,
2013).
Global genetic deletion of CaMKIId has been shown to attenuate
pathological cardiac remodeling induced by transverse aortic
constriction (TAC), a model of pressure overload-induced heart
failure (Backs et al, 2009; Ling et al, 2009). However, little is
known about the effects of a global CaMKIId knockout (KO) in the
context of MI or I/R. For example, the biological stress and neuro-
humoral milieu are markedly different in acute ischemic injury and
later adaptation to infarction, and both differ from a simple
increase in after load. Recently, it was demonstrated that CaMKIId
mediates nuclear factor-jB (NF-jB) activation in cardiomyocytes
after in vivo I/R in mice and suggested that CaMKIId serves to trig-
ger changes in inflammatory gene expression that contribute to
myocardial I/R damage. In this study, CaMKIId KO mice were
protected against I/R damage as evidenced by decreased infarct
size, attenuated apoptosis, and improved functional recovery (Ling
et al, 2013). However, it remains unclear to what extent redundant
effects mediated by CaMKIIc play a role in the heart, as both
isoforms, d and c, are activated in response to chronic stress
(Colomer et al, 2003). In addition, the specific roles of CaMKIId
splice variants dB and dC in the context of I/R injury have not
been investigated yet. Other studies addressing the role of CaMKII
in myocardial infarction (MI) or I/R have been reported. Protective
effects of CaMKII inhibition have also been observed in experi-
ments using non-genetic approaches, for example, overexpression
of peptides or pharmacologic compounds such as KN-93 (Zhang
et al, 2005; Yang et al, 2006; Vila-Petroff et al, 2007; Joiner et al,
2012). These approaches face two limitations: (i) The inhibition of
CaMKII, such as assessed by phospholamban phosphorylation, was
not complete (Zhang et al, 2005). (ii) Off-target effects, for exam-
ple, on protein kinase D and ion channels have been observed
(Gao et al, 2006; Rezazadeh et al, 2006; Backs et al, 2009). There-
fore, we aimed to investigate the essential and specific roles of the
cardiac CaMKII isoforms using new genetic models. We used a
clinically relevant in vivo paradigm of myocardial I/R, closely
resembling the patient setting of acute MI and revascularization
therapy.
Results
CaMKIId does not regulate myocardial damage shortly after
I/R injury
To determine whether the most abundant cardiac CaMKII isoform,
CaMKIId, is critical for myocardial I/R injury, we used CaMKIId-
deficient mice (dKO). We used the same time course for I/R injury in
our KO mouse model as it was used before (LAD occlusion for 60 min
followed by 24 h reperfusion) (Ling et al, 2013). The ischemic area,
normalized to total heart volume, did not significantly differ between
wild-type (WT) and dKO mice, as assessed by Evans Blue staining.
In contrast to the recent report (Ling et al, 2013), no difference was
observed in the size of whitened triphenyltetrazolium chloride
(TTC)-stained infarct zone/ischemic area percentage (Fig 1A and B).
We also determined the extent of apoptotic cell death after myocar-
dial I/R injury by TUNEL assays. Hearts from mice that underwent
I/R surgery showed a distinct increase of TUNEL-positive cells as
compared to sham controls, but no difference between WT and dKO
animals could be detected (Fig 1C and D). Consistently, I/R led to a
similar increase in caspase-3/7 enzyme activity in WT and dKO mice
(Fig 1E). Because both apoptosis and necrosis mediate cell death in
MI and I/R (Saraste et al, 1997; James, 1998; McCully et al, 2004),
we also measured high-sensitive cardiac Troponin T (hsTnT) serum
levels as a marker for myocardial cell death. Repeated measurements
of serum hsTnT at defined time points after I/R surgery in a group of
WT mice showed that hsTnT serum time course was similar to
serum kinetics observed in patients after MI (Supplementary Fig
S1A) (Katus et al, 1991). In addition, a linear correlation between
hsTnT serum levels and planimetrically calculated infarct sizes was
observed (Supplementary Fig S1B). Based on these results, serum
hsTnT measurements were performed in all animals 24 h after I/R
surgery. Again, no significant difference was observed between WT
and dKO mice (Fig 1F), indicating that the global deletion of
CaMKIId does not affect myocardial damage shortly after I/R. In
order to test for infarct size differences at an earlier time point of
ischemic injury, we performed I/R experiments to compare I/R
damage in WT and CaMKIIdKO mice after only 30 min of ischemia.
Again, no significant difference between the groups could be found
(Supplementary Fig S2). To confirm, that the chosen experimental
setup is able to detect changes in acute I/R injury caused by other
interventions, we pretreated one group with enalapril as reported
before (Leuschner et al, 2010). As expected, enalapril led to a signifi-
cant reduction of infarct size (Supplementary Fig S3).
Role of CaMKIId splice variants in acute myocardial I/R injury
Recently, it has been shown that in a rat animal model, shortly after
I/R injury, expression of CaMKIId splice variants dB and dC are
inversely regulated, with CaMKIIdC showing increased expression
levels (Peng et al, 2010). In order to investigate expression of
CaMKII and its splice variants after mouse I/R injury, a group of
WT animals underwent in vivo I/R surgery. After reperfusion peri-
ods of either 1 or 5 days, hearts were harvested to analyze CaMKII
expression by Western blot. Because it was shown that mitochon-
drial-targeted CaMKII inhibition protects against myocardial I/R
injury (Joiner et al, 2012), we analyzed CaMKII expression levels
both in mitochondria and the cytoplasm. As depicted in Fig 2A,
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Figure 1. CaMKIId deletion does not affect infarct size in ischemia/reperfusion injury.
I/R surgery was performed in Camk2d/ C57BL/6 (dKO) and wild-type C57BL/6 (WT) mice.
A Transverse heart sections were obtained from WT and dKO mice 24 h after myocardial I/R injury. All sections were stained with Evans Blue and TTC. Representative
images are shown. Scale bar: 2 mm.
B Quantitative measurement of ischemic area/total heart volume ratio and infarct zone/ischemic area ratio was performed. Planimetrically and volumetrically
calculated infarct sizes show no significant differences. N = 8 animals operated and analyzed in dKO group, 10 animals in WT group. Infarct zone/ischemic area: ns,
P = 0.33. Ischemic area/total heart volume: ns, P = 0.45.
C Representative photomicrographs showing TUNEL staining of WT and dKO left ventricular (LV) transverse sections 24 h after myocardial I/R injury or sham operation.
Positive: pretreatment with DNase I; negative: without TUNEL enzyme solution. Scale bar: 50 lm. (upper) DAPI, (middle) TUNEL, (lower) merge.
D Quantification of TUNEL-positive cells per 100 DAPI-positive nuclei. N = 5 animals per group. ns, P = 0.37; *P = 0.04; **P = 0.01.
E Caspase-3/7 enzyme activity was measured in LV homogenates. Values are normalized to caspase-3/7 activity in septal myocardium. N = 3 animals per group. ns,
P = 0.84; *P = 0.02 in WT group; *P = 0.04 in dKO group.
F High-sensitive serum Troponin T (hsTnT) was measured 24 h after myocardial I/R injury. N = 5 animals in WT sham group, 11 animals in WT I/R group, 10 animals in
dKO sham group, 8 animals in dKO I/R group. ns, P = 0.08; ***P = 0.0007 in WT group; ***P = 0.0001 in dKO group.
Data information: All data are expressed as mean  SEM. Unpaired Student’s t-test (B) and one-way ANOVA with Bonferroni’s multiple comparison test (D–F) were used
to compare groups. ns = non-significant.
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24 h after I/R surgery, a shift in cytoplasmic CaMKIId splice variant
expression toward increased levels of CaMKIIdC could be detected,
which was emphasized after 5 days. Interestingly, we could not
detect any shift or increased expression levels of total CaMKII in the
mitochondrial fraction after 1 day. However, there was a trend
toward increased CaMKIIdC expression levels after 5 days. The
purity of the mitochondrial fraction was confirmed by Western blot
analysis against Cox IV (Supplementary Fig S4). In the available
CaMKIId KO mice (Backs et al, 2009; Ling et al, 2009, 2013),
CaMKIId is deleted along with its splice variants including dB and
dC. Because it was suggested that dB and dC play opposite roles in
the context of ischemic stress (Maier et al, 2003; Zhu et al, 2003,
2007; Little et al, 2009; Peng et al, 2010), and considering the shift
in splice variant expression after I/R injury as described above, we
hypothesized that the specific deletion of the dC splice variant might
protect the heart against acute I/R injury. Thus, we took advantage
of the cardiotrophic adeno-associated virus 9 (AAV9) in vivo expres-
sion system (Goehringer et al, 2009) and re-expressed dB and dC
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Figure 2. CaMKIId splice variants dB and dC are not critical for acute I/R injury.
A CaMKII expression after I/R injury. WT mice underwent surgery and were challenged by 60 min of ischemia followed by either 24 h or 5 days of reperfusion. LV
homogenates were further processed to obtain cytoplasmic and mitochondrial fractions. (Top) CaMKII expression levels as detected by Western blot analysis are
shown. Upper band represents CaMKIIdB, lower band CaMKIIdC splice variant (Bottom). Bar graphs quantify splice variant shift, depicted as dC/dB ratio. N = 3 in
sham groups, 4 in I/R groups. *P = 0.04; **P = 0.01 versus sham; ***P = 0.0009 versus sham. To confirm the specificity of the CaMKII band, LV homogenates of mice
lacking the two CaMKII genes delta and gamma (DKO, see also Fig 3) were loaded.
B AAV9 vectors containing myc-tagged CaMKIId splice variants dB or dC were designed and produced. Numbers in boxes represent CaMKIId exon numbers.
NLS = nuclear localization sequence (exon 14), ITR = inverted terminal repeat sequence, CMV-enh = cytomegalovirus enhancer, MLC260 = myosin light chain 260
promoter, polyA = polyadenylation tail. Camk2d/ mice received a single tail vein injection of 5 × 1011vg AAV9-CaMKIIdB (dB) or AAV9-CaMKIIdC (dC). I/R surgery
was performed after 4 weeks.
C Transverse heart sections were obtained from mice expressing CaMKIIdB or dC at 24 h after myocardial I/R injury. All sections underwent Evans Blue and TTC
staining. Representative images are shown. Scale bar: 2 mm.
D Quantitative measurements of ischemic area/total heart volume ratio and infarct zone/ischemic area ratio were performed. Planimetrically and volumetrically
calculated infarct sizes did not differ significantly: ns, P = 0.91. Ischemic area/total heart volume: ns, P = 0.54. N = 8 animals per group operated and analyzed in
dCKO group, 7 animals in dBKO group.
E Representative photomicrographs showing TUNEL staining in dCKO and dBKO LV transverse sections 24 h after myocardial I/R injury or sham operation. Positive:
pretreatment with DNase I; negative: without TUNEL enzyme solution. Scale bar: 50 lm. (upper) DAPI, (middle) TUNEL, (lower) merge.
F Bar graphs show quantification of TUNEL-positive cells per 100 DAPI-positive nuclei. N = 3 animals in sham groups, 4 animals in I/R groups. ns, P = 0.27; **P = 0.006
in dCKO group; **P = 0.004 in dBKO group.
G hsTnT was measured 24 h after myocardial I/R injury. N = 4 animals in sham groups, 8 animals in dCKO group, 7 animals dBKO group. ns, P = 0.94; **P = 0.002;
***P = 0.0006.
Data information: All data are expressed as mean  SEM. Unpaired Student’s t-test (D) and one-way ANOVA with Bonferroni’s multiple comparison test (A, F and G)
were used to compare groups. ns = non-significant.
Source data are available online for this figure.
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under the control of a CMV-enhanced MLC260 promotor (Geisler
et al, 2011; Schinkel et al, 2012) in the CaMKIId-KO background,
which resulted in a functional KO of the non-expressed counterpart
(Fig 2B). This enabled us to titrate the AAV9-MLC260-dC and
AAV9-MLC260-dB virus concentrations to a degree that allowed
expression close to endogenous CaMKII levels (Supplementary Fig
S5A). Doing so, we could reduce the likelihood that unspecific
effects occur as discussed for the alternative overexpression
approach by the use of transgenic CaMKIIdB/CaMKIIdC mice
(Zhang et al, 2002, 2003). Based on the titration experiment, we
next injected 5 × 1011 virus particles of AAV9-MLC260-CaMKIIdB
(dCKO) or AAV9-MLC260-CaMKIIdC (dBKO) into CaMKIId-KO mice
to create mice specifically lacking only one of the two splice vari-
ants. At baseline, AAV9-injected mice did not differ with respect to
cardiac function, assessed by echocardiography (Supplementary Fig
S5B). Then, these mice underwent I/R surgery. As depicted in
Supplementary Fig S5C, CaMKIIdC splice variant was significantly
upregulated after 60 min of ischemia and 24 h of reperfusion, while
there was only a trend toward an upregulation of CaMKIIdB splice
variant. In order to test CaMKII function of AAV9 splice variants,
we expressed CaMKIIdB and CaMKIIdC splice variants in CaMKIId
KO mice and measured PLN-P-Thr17 phosphorylation as indicator
for CaMKII activity by Western blot analyses. Reduced PLN phos-
phorylation at Thr17 in CaMKIId KO samples was restored by
CaMKIId splice variant expression (Supplementary Fig S5D).
Surprisingly, quantification of ischemic areas, normalized to total
heart volumes, revealed no significant differences in areas at risk
between dCKO and dBKO mice after I/R injury. Moreover, infarct
sizes did not differ between the groups (Fig 2C). Consistently,
no significant differences were observed in apoptotic or necrotic
markers, analyzed by TUNEL-staining and serum hsTnT measure-
ments (Figs 2D and 3F).
Combined cardiomyocyte-specific deletion of CaMKIId/c does not
affect I/R injury
To test the possibility that CaMKIIc compensates for CaMKIId, we
aimed to use CaMKIId/c double KO mice. Because the combined
global deletion of CaMKIId and c resulted in early postnatal lethal-
ity, we generated double-floxed CaMKIId/c mice (CaMKIIcloxP/loxP;
CaMKIIdloxP/loxP, here termed as FFFF) and crossed them with mice
expressing Cre-recombinase under the control of the cardiomyocyte-
specific a-MHC-promoter (Agah et al, 1997) to receive cardiomyo-
cyte-specific CaMKIId/c double KO mice (DKO). To determine the
degree of CaMKII deficiency, we performed Western blot analysis
with ventricular protein extracts using an antibody directed against
CaMKIId and c (Backs et al, 2009, 2010), and against the well-
characterized CaMKII-phosphorylation site Thr-17 of phospholamban
(PLN) to estimate CaMKII activity (Fig 3). The deletion of CaMKIId
led to a dramatic reduction of CaMKII protein but only to a moder-
ate loss of PLN-Thr17 phosphorylation, indicating that CaMKIIc,
which we found to contribute only to a very small degree to the
detectable CaMKII level, compensates for CaMKIId. Consistent with
this hypothesis, DKO hearts showed a dramatic loss in PLN-Thr17
phosphorylation. The residual CaMKII signal in DKO likely reflects
CaMKII expression in non-cardiomyocytes. Thus, we also confirmed
these differences between single and double KO mouse models in
isolated adult cardiomyocytes (Supplementary Fig S6).
We then performed I/R surgery in FFFF and DKO mice.
Despite the complete loss of CaMKII activity in DKO, infarct size
CaMKII
PLN-P-Thr17
PLN-P-Ser16
PLN-total
GAPDH
56
10
10
10
36
WT δKO γKO DKO FFFF
KDa
Figure 3. CaMKIId and c KO mouse models.
To rule out redundant effects of myocardial CaMKIIc isoform, cardiomyocyte-specific CaMKIIc/d double KO mice were created [Camk2cloxP/loxP; Camk2dloxP/loxP; a-MHC-Cre
(DKO) and Camk2cloxP/loxP; Camk2dloxP/loxP (FFFF)]. LV homogenates were subjected to Western blot analysis using antibodies directed against CaMKII, phospho-PLN-Thr17,
phospho-PLN-Ser16, PLN, and GAPDH. Although CaMKII expression at the protein level is decreased in both CaMKII delta single KO animals (dKO) and DKO, significant
reduction of CaMKII-phosphorylated phospholamban (PLN) at Thr17 can only be seen in DKO hearts. Total amounts of PLN, GAPDH, and PLN at the PKA phosphorylation site
Ser16 served as loading control. cKO: CaMKII gamma single KO; WT: wild-type.
Source data is available online for this figure.
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quantification of Evans Blue- and TTC-stained transverse sections
revealed no significant differences between FFFF and DKO (Fig 4A
and B). Consistent with the macroscopic findings, no significant
differences were observed in apoptotic or necrotic markers, as
analyzed by TUNEL-staining, caspase-3/7 activity measurements
and serum hsTnT measurements (Fig 4C–F).
Inducible CaMKIId and c deletion does not protect against acute
I/R injury
Given the high number of related cardiac signaling pathways
involved in cellular responses to MI (Pfeffer & Braunwald, 1990;
Kehat & Molkentin, 2010), the possibility exists that another path-
way compensates for CaMKIId/c in the context of ischemia, which
might not be reflected by PLN-Thr17 phosphorylation. Because
compensation occurs more likely in congenital loss-of-function
models, we sought to investigate the effects of I/R in an inducible
DKO mouse model. Thus, we directed expression of Cre-recombinase
to the adult heart using cardiotrophic AAV9 vectors. In this vector
(AAV9-MLC260-Cre), Cre is expressed under the control of a
CMV-enhanced MLC260 promotor (Supplementary Fig S7A). By this
method, we achieved after 12 weeks a substantial CaMKII downre-
gulation and a clear reduction in PLN-Thr17 phosphorylation by a
single intravenous (i.v.) injection of AAV9-MLC260-Cre into FFFF
(Supplementary Fig S7B and C). In unstressed FFFF mice, the AAV9
treatment did not affect cardiac function assessed by echocardiogra-
phy (Supplementary Fig S7D). We then performed I/R surgery on
FFFF mice 12 weeks after treatment with AAV9-MLC260-Cre (iDKO)
and as a control 12 weeks after treatment with AAV-MLC260-Luc
(expression of luciferase under the control of MLC260). By Western
blot analysis, we confirmed a sufficient CaMKII take out in all exper-
imental iDKO mice. But again, assessment of infarct size did not
demonstrate any significant difference of infarct zone/ischemic area
ratios between the groups (Supplementary Fig S7E and F). More-
over, no significant differences were observed in apoptotic or
necrotic markers, as analyzed by TUNEL-staining and serum hsTnT
measurements (Supplementary Fig S7G–I).
CaMKII DKO mice show a reduced infarct size and improved
cardiac function 5 weeks after I/R surgery
We next tested the hypothesis that genetic deletion of cardiac
CaMKII protects the heart only in a long-term follow-up I/R study.
Therefore, we performed I/R surgery on DKO and FFFF mice accord-
ing to an extended protocol of 60 min LAD occlusion, followed by
5 weeks of reperfusion. To rule out surgery related differences of
infarct sizes between the groups, we obtained blood for serum
hsTnT measurements 24 h after surgery, confirming similar infarct
sizes in the experimental groups shortly after I/R injury (Fig 5A).
We then performed echocardiography 2, 3 and 4 weeks after I/R
surgery to assess cardiac function. Strikingly, FFFF I/R mice showed
a progressive deterioration of cardiac function from 2 to 4 weeks
post-surgery, while this functional impairment was ameliorated in
DKO mice after 4 weeks (Fig 5B). At 5 weeks after I/R injury, all
mice were subjected to hemodynamic characterization. Invasive
parameters clearly indicate a significantly higher ejection frac-
tion (EF) in DKO mice compared to FFFF controls (Fig 5C and
Table 1). Histological infarct size quantification revealed reduced
scar formation in response to I/R in DKO as compared to FFFF
controls. Moreover, the degree of fibrosis, as seen at higher magnifi-
cation, was apparently less dense in DKO (Fig 5D). Taken together,
these findings most likely account for improved cardiac function in
DKO mice. Similar data were obtained in an independent experi-
ment with a follow-up of 6 weeks after surgery. We followed these
mice by echocardiography with a Visual Sonics Vevo 2100 instru-
ment to measure endocardial fractional area change (FAC), which
represents cardiac function and specifically detects regional contrac-
tion deficits due to infarct scars. Here, we found again an improved
cardiac function of DKO mice at 6 weeks after I/R surgery, as
compared to FFFF controls. In addition, we repeated invasive
pressure-volume analyses, confirming increased ejection fraction
and decreased dilation parameters in DKO hearts (Supplementary
Fig S8).
CaMKII mediates cardiac leukocyte infiltration and
chemoattractant signaling
Next, we hypothesized that the attenuation of post-infarct remodel-
ing might be mediated by inflammatory processes. In order to inves-
tigate the kinetics of leukocyte infiltration after I/R injury, we
performed flow cytometric analyses in a time course of one and
5 days after I/R surgery. We observed reduced infiltration of CD45+
leukocytes 5 days after I/R injury in DKO mice, while no significant
differences were observed 1 day after I/R injury, possibly explaining
the late effects of CaMKII deletion (Fig 6A and B). To identify
CaMKII-dependent inflammatory pathways, we performed unbiased
and systematic RNA analyses by Affymetrix chip arrays in cardiac
samples at 1 and 5 days after I/R injury versus sham-operated
hearts. Gene Set Enrichment Analysis (GSEA) was then used to
determine whether defined sets of genes exhibit a statistically signif-
icant bias in their distribution within a ranked gene list (Subramanian
et al, 2005). Pathways belonging to specific cell functions were
obtained from public external databases (KEGG PATHWAY Data-
base, http://www.genome.jp/kegg/) to perform pathway analyses.
Doing so, we identified several inflammatory pathways to be attenu-
ated in DKO as compared to FFFF (Supplementary Fig S9A). Intrigu-
ingly, the “Chemokine Signaling Pathway” was attenuated at both 1
and 5 days after I/R. Whereas several ligands to inflammatory cells
were attenuated 1 and 5 day after I/R, the expression of intracellular
components of inflammatory cells were mostly attenuated 5 days
after I/R, confirming an attenuated infiltration of inflammatory cells
at this time point (Supplementary Fig S9B). We then validated the
top 5 attenuated genes of the “Chemokine Signaling Pathway” at the
1 and 5 day time point after I/R by RT–PCR (Supplementary Fig
S9C), and we could confirm an attenuated gene expression of CCL3,
CCR1, CXCR2, PPBP, HCK, FGR, and CCL6. However, CXCL3 could
not be detected by RT–PCR and VAV1 and CCL2 could not formally
be validated, although a not statistically significant trend toward
attenuated expression could be noted. Based on the observation that
5 days after I/R more intracellular components of inflammatory
cells were enriched, we speculated that these changes are rather
indirectly and secondarily mediated by CaMKII by non-cardiomyo-
cyte autonomous effects. Vice versa, we envisioned that the chemo-
attractant ligands, which were already attenuated 1 day after I/R,
might be induced by CaMKII in cardiomyocytes. Thus, we tested
whether adenoviral expression of active CaMKII (CaMKII-T287D)
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Figure 4. Combined cardiomyocyte-specific deletion of CaMKIId/c does not affect I/R injury.
DKO mice underwent I/R surgery [Camk2cloxP/loxP; Camk2dloxP/loxP; a-MHC-Cre (DKO) versus Camk2cloxP/loxP; Camk2dloxP/loxP (FFFF)].
A Images of representative transverse heart sections after Evans Blue and TTC staining. Scale bar: 2 mm.
B Planimetrically and volumetrically calculated infarct sizes show no significant differences. N = 9–13 animals operated and analyzed per group. ns, P = 0.86. Ischemic
area/total heart volume: ns, P = 0.48.
C Representative photomicrographs of TUNEL-stained LV transverse sections after I/R or sham surgery. Positive: pretreatment with DNase I; negative: without TUNEL
enzyme solution. Scale bar: 50 lm. (upper) DAPI, (middle) TUNEL, (lower) merge.
D Bar graphs show quantification of TUNEL staining. N = 3 animals per sham group, 4 animals in FFFF group, 5 animals in DKO group. ns, P = 0.42; *P = 0.04 in FFFF
group; *P = 0.01 in DKO group.
E Caspase-3/7 enzyme activity was measured in LV homogenates. N = 2 animals per sham group, 3 animals in FFFF group, 4 animals in DKO group. ns, P = 0.32;
*P = 0.04; **P = 0.006.
F hsTnT was measured 24 h after ischemia. N = 5 animals per sham group, 9 animals in FFFF group, 13 animals in DKO group. ns, P = 0.79; *P = 0.04; ***P = 0.0005.
Data information: Data are expressed as mean  SEM. Unpaired Student’s t-test (B) and one-way ANOVA with Bonferroni’s multiple comparison test (D–F) were used to
compare groups. ns = non-significant.
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Figure 5. Improved cardiac function and reduced scar formation in DKO 5 weeks after I/R surgery.
DKO and FFFF littermates were subjected to I/R with 5 weeks of follow-up. Echocardiography was performed at 2, 3 and 4 weeks post-surgery. At 5 weeks, invasive
hemodynamic parameters were assessed and hearts were harvested for histological analysis.
A hsTnT was measured 24 h after myocardial I/R injury and revealed equal infarcts sizes in DKO and FFFF at this time point. N = 6 animals in sham groups, nine
animals in FFFF I/R group, 10 animals in DKO I/R group. ns, P = 0.68; **P = 0.001 in FFFF group; **P = 0.003 in DKO group.
B Transthoracic echocardiography revealed a significant difference in fractional shortening (FS) between FFFF and DKO 4 weeks after I/R surgery. N = 12 animals in
FFFF sham group, 11 animals in DKO sham groups, 13 animals in I/R groups.
C Representative pressure–volume loops showing improved hemodynamic cardiac function in DKO as compared to FFFF controls. Cardiac ejection fraction (EF) was
assessed and revealed a decrease in EF from 60.6  4.4 to 44.1  10.5 in FFFF mice after I/R surgery. No significant decrease in EF in DKO mice (61.3  11.4 to
53.5  10.6) was observed. N = 9 animals per sham group, 13 animals per I/R group. ns, P = 0.11; **P = 0.004; #P = 0.04.
D Representative images showing Masson’s trichrome staining of transverse cardiac sections. Rectangular selections are shown in greater magnification below. Section
plane: 3 mm above the heart apex. Scale bars: 2 mm (upper) and 500 lm (lower). Bar graphs show infarct size quantification expressed as scar area per LV area.
N = 5 animals in FFFF group, 7 animals in DKO group. **P = 0.001.
Data information: Data are expressed as mean  SEM. Unpaired Student’s t-test (D) and one-way ANOVA with Bonferroni’s multiple comparison test (A and C) were
used to compare groups. ns = non-significant.
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was sufficient to induce mRNA expression of selected genes of the
“Chemokine Signaling Pathway”. Strikingly, CaMKII induced only
expression of members of the chemokine (C-C motif) ligand family
(Fig 6C), in particular CCL2 (also known as monocyte chemotactic
protein 1, MCP1) and even more pronounced CCL3 (also known as
macrophage inflammatory protein 1 alpha, MIP-1 alpha) but not
CCR1, VAV1, HCK, or FGR (Supplementary Fig S10), which accord-
ing to the KEGG PATHWAY Database are all intracellular compo-
nents of inflammatory cells, supporting our hypothesis that these
genes are rather indirectly and secondarily regulated by CaMKII via
non-cardiomyocyte autonomous effects. To rule out an artificial
effect due to adenovial infections of NRVMs, we used another
adenovirus with a high titer (10 MOI), in this case NFAT-GFP, as a
control and found no effect on CCL2 and CCL3 expression. In these
experiments, CaMKII expression was confirmed by RT–PCR (3 MOI
led to a 18-fold increase in CaMKII expression and 10 MOI to a
114-fold increase).
To further support these data, we asked whether CaMKII is also
required for CCL2 and CCL3 gene expression in isolated cardio-
myocytes. Thus, we isolated adult mouse ventricular myocytes
(AMVMs) from FFFF and DKO and applied hypoxia followed by
8 h normoxia (Fig 6D). We found that CCL3 but not CCL2 was
significantly upregulated by hypoxia, which was clearly attenuated
in DKO cardiomyocytes. Taken together, CaMKII is sufficient and
required for cardiomyocyte autonomous CCL3 expression. To test
whether an increased gene expression of CCL2 and CCL3 results in
an increased secretion of the protein, we performed hypoxia exper-
iments in NRVMs (Fig 6E and F) and found that an increase in
CCL2 and CCL3 mRNA preceded an actual increase of CCL2 and
CCL3 protein in the supernatant of NRVMs 24 h after hypoxia,
potentially explaining the late effects on infiltration of CD45+
cells.
Discussion
The present study investigated for the first time the specific roles
of CaMKIId, its splice variants dB and dC, and potential redun-
dant roles of CaMKIId and CaMKIIc in the acute setting of in vivo
I/R injury and post-infarct remodeling. The important new finding
of this work is that CaMKII mediates maladaptive post-infarct
remodeling not through a reduction of acute myocardial damage
after I/R injury as reported by others.
CaMKII loss-of-function models
Because of the lack of sufficient CaMKII loss-of-function models,
one could not comprehensively study the essential roles of the
CaMKII genes and splice variants in the context of cardiovascular
disease. Therefore, we focused first on the development of genetic
mouse models, in which the cardiac CaMKII genes and splice vari-
ants were specifically targeted or re-expressed close to endogenous
levels in vivo. These models were then combined with a clinically
relevant in vivo I/R mouse model, resembling a common clinical
course of events in patients with MI who undergo revascularization
therapy. In contrast to previously described approaches aiming at
inhibiting CaMKII, the models established for this study are specific
and result—in case of DKO—in a profound and almost complete
inhibition of CaMKII activity. The DKO model is so far the most
effective approach to fully inhibit cardiac CaMKII activity in vivo.
Other published in vivo models that use either chemical compounds
or peptides or single CaMKII KOs did not result in a comparable
CaMKII loss of function as shown here by PLN-Thr17 hypo-phos-
phorylation (Zhang et al, 2005; Yang et al, 2006; Backs et al, 2009;
Ling et al, 2009, 2013). We also established an inducible DKO
model, which we currently also use to further evaluate CaMKII as a
Table 1. Morphologic features and hemodynamic analysis of CaMKII DKO and FFFF mice, 5 weeks after I/R surgery
FFFF DKO
Sham I/R Sham I/R
Heart weight (mg) 125.0  16.0 127.0  12.5 144.0  22.4 139.7  13.8
Body weight (g) 27.2  2.1 26.7  2.1 27.5  2.9 26.0  2.9
HW/BW ratio (mg/g) 4.6  0.3 4.4  1.4 5.2  0.4 5.2  0.4
Heart rate (bpm) 358.4  29.5 360.0  34.5 401.4  30.2 390.3  40.1
Ejection fraction (%) 60.6  4.4 44.1  10.9† 61.3  11.4 53.5  10.6‡
dP/dtmax (mmHg/s) 5,514  1300 4,477  1993 6,065  989 5,702  1661
dV/dtmax (lL/s) 1,360  546 1,295  486 1,536  498 1,445  531
LVESP (mmHg) 103.3  13.2 83.6  12.0† 105.0  14.8 93.6  9.2‡
LVEDP (mmHg) 3.6  1.3 3.6  1.9 2.8  0.9 3.3  1.2
SV (lL) 25.1  4.4 20.1  5.8* 25.8  5.5 24.7  9.2
Tau (ms) 11.6  2.2 12.1  2.0 9.8  1.1 11.6  3.0
HW/BW, heart weight/body weight ratio; LVESP, LV end-systolic pressure; LVEDP, LV end-diastolic pressure; SV, stroke volume; Tau, time constant of pressure
relaxation.
CaMKII DKO and FFFF mice were subjected to hemodynamic detection 5 weeks after I/R surgery. Data are expressed as mean  SD of values from nine mice in
sham groups and 13 mice in I/R groups.
*P < 0.05.
†P < 0.01 versus sham FFFF.
‡P < 0.05 versus I/R FFFF.
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therapeutic target in cardiovascular disease by deleting CaMKII after
onset of disease. The AAV9-Cre driven gene take out did neither
induce AAV- nor Cre-associated cardiomyopathy as it was reported
for an alternative approach, in which tamoxifen is used in combina-
tion with Mer-Cre-Mer transgenic mice (Koitabashi et al, 2009;
Molkentin & Robbins, 2009). However, we cannot formally rule out
that in the DKO or iDKO model, CaMKIIb may compensate for the
loss of CaMKIId and CaMKIIc. Moreover, we established a CaMKII
gene replacement strategy to study the specific functions of the
CaMKIId splice variants dB and dC. This is of particular interest in
the context of I/R injury because it was suggested that dC plays
rather a maladaptive and dB rather a protective role in this process
(Zhang et al, 2003, 2010; Zhu et al, 2003, 2007; Little et al, 2009;
Peng et al, 2010). Thus, we were interested to test whether the
specific lack of CaMKIIdC protects the heart against acute myocar-
dial I/R injury. We took advantage of the AAV9-mediated expres-
sion approach to re-express the CaMKII splice variants at
endogenous rather than at artificial overexpression levels. In this
regard, CMKIIdB and CMKIIdC transgenic mice showed at least a 10-
fold overexpression of CaMKII in the heart (Zhang et al, 2002,
2003), which exceeds the expression levels as observed in patholog-
ical conditions (see Fig 2).
CaMKII in acute I/R injury
Previous work suggested that CaMKII inhibition prevents adverse
remodeling following MI (Zhang et al, 2005). Furthermore, evidence
was provided that CaMKII mediates apoptosis in the acute setting of
MI (Yang et al, 2006; Joiner et al, 2012). In these studies, CaMKII
inhibition was achieved by cardiac expression of a CaMKII inhibi-
tory peptide, which may also exert CaMKII-independent effects
(Backs et al, 2009). Therefore, the possibility exists that the
inhibition of other signaling molecules accounts for the early anti-
apoptotic effects. In another study, pharmacological CaMKII
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Figure 6. CaMKII mediates infiltration o CD45+ cells and pro-inflammatory chemoattractant signaling.
A Representative dot plots of hearts analyzed by flow cytometry comparing sham operated, I/R d1 and I/R d5 from DKO and FFFF control animals. Blue gates indicate
CD45+ cells. N = 5 animals per sham group, 6 animals per I/R group.
B Quantitative analysis. Reduced infiltration of CD45+ leukocytes occurs 5 days after I/R injury in DKO mice, while no significant differences can be detected on day 1
after I/R injury. ns, P = 0.86; ***P = 0.0004.
C Gene expression as determined by real-time RT–PCR of CCL2 and CCL3 in NRVMs under control conditions and after adenoviral infection with active CaMKII (contains
T287D mutation for auto-activation) or NFAT-GFP as additional control. Gene expression is normalized to GAPDH. N = 6 independent experiments per group.
***P = 0.0001 in CCL2 group; **P = 0.002; ***P = 0.0001 in CCL3 group.
D Gene expression as determined by real-time RT–PCR of CCL2 and CCL3 in adult mouse ventricular myocytes (AMVMs) from FFFF and DKO mice (n = 6 wells per
condition) after hypoxia, normalized to GAPDH. ns, P = 0.68 in FFFF group; ns, P = 0.29 in DKO group; *P = 0.01.
E Gene expression as determined by real-time RT–PCR of CCL2 and CCL3 in NRVMs after hypoxia followed by normoxia periods as indicated, normalized to GAPDH,
respectively. N = 4 wells per condition. *P = 0.02; **P = 0.006 in CCL2 group; *P = 0.01 (6 h); *P = 0.02 (24 h) in CCL3 group.
F Quantification of CCL2 and CCL3 protein as determined by ELISA in supernatant from NRVMs after hypoxia followed by normoxia periods as indicated. N = 3 per
condition. *P = 0.03 in CCL2 group; *P = 0.04 in CCL3 group.
Data information: Data are expressed as mean  SEM. One-way ANOVA with Bonferroni’s multiple comparison test was used to compare groups. ns = non-significant.
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inhibition resulted in smaller infarct sizes and significant reductions
of apoptotic and necrotic markers in acute I/R of isolated
Langendorff-perfused rat hearts (Vila-Petroff et al, 2007). Here,
KN-93 was used as pharmacological inhibitor of CaMKII. Although
commonly used, KN-93 was also shown to induce general toxicity
and to lack specificity for CaMKII (Means, 2000; Hudmon &
Schulman, 2002; Gao et al, 2006; Rezazadeh et al, 2006).
The first study to report protective effects in a genetic CaMKIId
mouse model in acute I/R injury was published very recently (Ling
et al, 2013). However, although we used the same protocol of
60 min of LAD ligation followed by 24 h of reperfusion, we could
not demonstrate beneficial effects in this setting. A possible expla-
nation for these contradictory results could be found in different
genetic backgrounds or different KO strategies. Deletion of CaMKIId
and CaMKIIc in the present study was achieved by targeting exons
1 and 2 of the two CaMKII genes, resulting in no residual transla-
tion of partial CaMKII peptides (Backs et al, 2009). In contrast, the
other CaMKIId-KO model (Ling et al, 2009, 2013) was generated by
targeting exons 9 to 11. Thus, the possibility exists that a residual
N-terminal CaMKII polypeptide is produced which exerts a domi-
nant-negative effect on CaMKIIc or modulatory effects on other
kinases because the N-terminal part would be predicted to bind to
CaMKII phospho-sites (which are often shared with other kinases)
but would not direct kinase activity to these sites. The present
study used the aforementioned genetic mouse models without
residual CaMKII peptides but could not confirm a critical role of
CaMKII after acute myocardial I/R injury. This conclusion based on
three pieces of evidence: First, there was no difference in infarct
sizes after 30 or 60 min of ischemia and subsequent 24 h of reper-
fusion. Second, neither apoptotic nor necrotic markers were signifi-
cantly different. Third, we confirmed these data in four different
CaMKII loss-of-function models: (i) KO of the major cardiac CaMKII
isoform d, (ii) functional KO of the major cardiac CaMKII splice
variants dB or dC, (iii) cardiomyocyte-specific DKO, to address the
redundant roles of CaMKIId and c, and (iv) induced cardiomyocyte-
specific DKO, to reduce compensatory mechanisms. Surprisingly,
but based on these extensive studies, we must conclude that
CaMKII—at least in the clinically relevant setting that was used in
this study—is not critical for infarct size determination after acute
myocardial ischemia/reperfusion injury in mice. Potential
arrhythmogenic effects of CaMKII were not directly investigated in
the present study. However, we did not observe any differences
with regard to acute mortality of the operated animals, allowing us
to assume that possible I/R-related arrhythmias were not CaMKII-
mediated.
CaMKII DKO alters leukocyte infiltration kinetics after I/R injury
Despite similar infarct sizes (based on hsTnT levels 24 h after ische-
mia) in FFFF and DKO mice, cardiac dysfunction failed to progress
3 weeks after I/R injury in DKO animals. The protection against
cardiac dysfunction was associated with reduced scar formation.
Thus, we searched for possible underlying mechanisms. Within the
early phase after I/R injury between day 1 and 5, inflammatory
signals recruit myeloid cells (neutrophils, monocytes/macrophages)
to the infarct zone, where different populations of these leukocytes
are responsible for clearance of dead cardiomyocytes and cell debris
(Leuschner et al, 2012). In addition, formation of granulation tissue
including promotion of new blood supply marks the beginning of
post-infarct remodeling (Ertl & Frantz, 2005; Frangogiannis, 2008).
It has been shown that distinct monocyte subsets contribute in
specific ways to myocardial ischemic injury. Two distinct phases of
monocyte participation after MI have been proposed: (I) Ly-6C hi
monocytes have been shown to dominate the early phase and
exhibit phagocytic, proteolytic, and inflammatory functions, while
(II) Ly-6C lo monocytes dominate the later phase by expressing
vascular endothelial growth factor and promoting healing via
myofibroblast accumulation, angiogenesis, and deposition of colla-
gen (Nahrendorf et al, 2007). In the present study, we used CD45
as a pan leukocyte marker to investigate general differences in
leukocyte infiltration kinetics in CaMKII DKO mice. While at day 1
after I/R injury, no difference in inflammatory leukocyte response
could be seen, we found altered leukocyte infiltration at day 5 after
I/R injury. Considering different phases of post-I/R inflammatory
processes and distinct functional differences of inflammatory cells
at specific time points in post-I/R remodeling (Nahrendorf et al,
2007), we postulated that CaMKII might be a key regulator of the
later inflammatory response after I/R—rather than an early regula-
tor of cell death and infarct size determination, as evidenced by our
acute I/R experiments (Figs 1, 2 and 4, Supplementary Figs S2
and S7).
How does CaMKII regulate cardiac inflammation?
Several previous studies reported protective effects of CaMKII inhi-
bition in the chronic process of pathological remodeling after
myocardial infarction or pathological pressure overload, which are
both characterized with the activation of inflammatory pathways
(Zhang et al, 2005; Backs et al, 2009; Ling et al, 2009; Yoo et al,
2009). Based on the conditional cardiomyocyte-specific knockout
strategy used in this study, we can rule out that CaMKII mediates
the inflammatory response by acting in inflammatory cells, in
cardiac fibroblasts or other non-myocyte cells because CaMKII was
specifically deleted in cardiomyoctes. Thus, we investigated whether
CaMKII may signal via chemoattractant signals to leukocytes. In
cardiomyocytes, CaMKII was shown to tightly regulate epigenetic
processes controlled by histone deacetylases (HDACs) leading to
transcriptional activation of gene programs that drive pathological
remodeling (Anderson et al, 2011). In particular, CaMKII regulates
HDAC4 and indirectly HDAC5, resulting in cytosolic accumulation
of these epigenetic enzymes (Backs et al, 2006, 2009). As a conse-
quence, gene programs that are controlled by the transcription
factors MEF2 and SRF are activated (Kreusser & Backs, 2014;
Lehmann et al, 2014). Cardiomyocyte-specific overexpression of
these transcription factors leads to pathological remodeling (Zhang
et al, 2001; Kim et al, 2008). However, leukocyte infiltration was
not studied in detail in these animal models, but MEF2 was recently
identified to be a critical part in inflammatory pathways in Drosophila
(Clark et al, 2013). Moreover, it has been recently described that
the CaMKII/HDAC4-HDAC5/MEF2-pathway (Backs et al, 2008)
regulates CCL2 in vascular smooth muscle cells (Ginnan et al,
2012). Here, we show for the first time that gene expression of CCL2
and CCL3 is induced by CaMKII in cardiomyocytes and that CaMKII
is required for hypoxia-induced CCL3 expression in cardiomyocytes.
Both CCL2 and CCL3 have been implicated in cardiac pathologies:
CCL2 (MCP-1) is a well-known chemokine involved in recruitment
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of leukocytes and regulated after myocardial infarction (Birdsall
et al, 1997). CCL3 has been described to be upregulated after
myocardial infarction, autoimmune myocarditis, and Chagas disease
due to trypanosoma cruzi infection (Goser et al, 2005; Machado
et al, 2008; Alves et al, 2012). However, the upstream signaling
pathways of CCL3 under these conditions were incompletely under-
stood. We now demonstrate that CaMKII is sufficient and required
for CCL3 expression in cardiomyocytes.
Clinical implications
We conclude that other than reported before CaMKII is not critical
for cardiomyocyte survival and infarct size determination in the first
24 h after myocardial infarction. However, at later time points,
combined deletion of the two cardiac CaMKII genes slows down the
process of I/R-mediated post-infarct remodeling and cardiac
dysfunction, possibly by attenuating pro-inflammatory chemoattrac-
tant signaling molecules such as CCL3. Therefore, CaMKII inhibition
might become a promising anti-inflammatory therapeutic strategy in
patients during post-infarct remodeling after myocardial infarction
and revascularization. Moreover, given the role of CCL3 in auto-
immune myocarditis and Chagas disease, CaMKII might also be a
promising drug target in these disease entities.
Materials and Methods
Animals
CaMKIId and CaMKIIc KO mice were described previously (Backs
et al, 2009, 2010). CaMKIId/CaMKIIc double knockout (DKO) mice
were created by crossbreeding double-floxed animals (CaMKIIcloxP/loxP;
CaMKIIdloxP/loxP, FFFF) with mice expressing Cre-recombinase under
the control of a cardiomyocyte-specific a-MHC-promoter (Agah et al,
1997). Inducible CaMKII double KO mice (iDKO) were created by
Cre-recombinase that was expressed under the control of a CMV-
enhanced 260-bp myosin light chain (MLC260) promotor and delivered
to the heart via cardiotrophic AAV9 (AAV9-MLC260-Cre) (Geisler et al,
2011). FFFF control mice received AAV9-MLC260-Luc (luciferase
expression). Briefly, 9 × 1011vg of AAV9-MLC260-Cre or AAV9-
MLC260-Luc were injected intravenously into tail veins of FFFF mice.
Subsequent I/R experiments were performed at 12–13 weeks after i.v.
injection. CaMKIId KO, DKO, and CaMKIId KO mice expressing
CaMKIId splice variants dB and dC were subjected to surgery at the
age of 10–15 weeks. Mice expressing AAV-Cre and AAV-Luc were
operated at 16–18 weeks of age. All animals were fed a standard
diet and water and were maintained on a 12-h light and dark cycle
at a room temperature of 22  2°C. All experimental procedures
were reviewed and approved by the Institutional Animal Care and
Use Committee at the Regierungspra¨sidium Karlsruhe, Germany.
Please see detailed Supplementary Methods providing methodo-
logical summary of in vivo I/R, high-sensitive cardiac Troponin T
measurements, chemical reagents, plasmids and generation of AAV
vectors, mitochondrial isolation, Western blot analysis, RNA micro-
array, RT–PCR, histology, TdT-mediated dUTP nick end labeling
(TUNEL), caspase-3/7 activity measurements, transthoracic echo-
cardiography, flow cytometry, primary cardiomyocyte cell culture
experiments, and P-V loop analysis.
Statistics
Data are presented as mean  SEM and were analyzed by Student’s
t-test between two groups or by ANOVA with Bonferroni’s multiple
comparison test when 3 or more groups were compared. A
P-value < 0.05 was considered statistically significant.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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Problem
CaM Kinase II (CaMKII), a serine/threonine protein kinase with a broad
spectrum of substrates, was suggested to mediate ischemic myocar-
dial injury and adverse cardiac remodeling. Recent studies investi-
gated the role of CaMKII in myocardial infarction and ischemia/
reperfusion injury (I/R), mostly using inhibitory peptides and pharma-
cologic agents. However, the specific functions of the cardiac CaMKII
genes and splice variants in I/R remained unclear.
Results
Here, we show that CaMKII is critically involved in the process of post-
infarct remodeling, but—other than reported before—not in the imme-
diate mechanisms that regulate acute damage after I/R injury. Using
flow cytometry and gene profiling, we found that CaMKII mediates
altered leukocyte infiltration kinetics and pro-inflammatory chemoattr-
actant signaling, indicating that CaMKII regulates pathological post-
infarct remodeling via inflammatory pathways rather than via early
induction of cell death. This was confirmed by the use of different new
genetic CaMKII KO mouse models: While (i) neither the single genetic
deletion of the CaMKIId isoform, nor (ii) a gene replacement strategy
with adeno-associated virus-mediated expression of the CaMKII splice
variants dB and dC, nor (iii) a cardiomyocyte-specific CaMKIId/c double
knockout (DKO) nor (iv) inducible DKO did reveal differences in infarct
size or cell death in acute I/R injury, 5 weeks after I/R injury, DKO mice
were protected against extensive scar formation and cardiac dysfunc-
tion, as assessed by trichrome staining, transthoracic echocardiography
and pressure-volume loop measurements.
Impact
CaMKII inhibition might become a promising therapeutic anti-inflam-
matory strategy in patients during post-infarct remodeling after
myocardial infarction and revascularization. However, other than
hypothesized, CaMKII inhibition seems not to prevent acute cardiac
damage 1 day after ischemia.
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